Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Demetri, G. D.
Right arrow Articles by Cella, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Demetri, G. D.
Right arrow Articles by Cella, D.

Journal of Clinical Oncology, Vol 16, 3412-3425, Copyright © 1998 by American Society of Clinical Oncology

ARTICLES

Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group

GD Demetri, M Kris, J Wade, L Degos and D Cella
Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA. george_demetri@dfci.harvard.edu

PURPOSE: To evaluate prospectively the effectiveness of epoetin alfa as an adjunct to chemotherapy in patients with cancer based on changes in quality-of-life parameters and hemoglobin levels, and to correlate these changes with antitumor response. PATIENTS AND METHODS: Two thousand three hundred seventy patients with nonmyeloid malignancies who received chemotherapy were enrolled onto this study from 621 US community-based practices. Patients received epoetin alfa 10,000 U three times weekly, which could be increased to 20,000 U three times weekly depending on the hemoglobin response at 4 weeks. Treatment continued for a maximum of 16 weeks in patients who showed evidence of hematologic response. RESULTS: Two thousand two hundred eighty-nine patients (97%) were eligible for efficacy analyses. Epoetin alfa therapy was associated with improved quality-of-life parameters; these improvements correlated significantly with hemoglobin levels and were independent of tumor response. Provider-reported Karnofsky performance scores did not correlate with the improved quality-of-life changes. Epoetin alfa therapy was also associated with a significant increase in hemoglobin levels and decrease in transfusion use. Tumor type, chemotherapy agent/regimen, prior chemotherapy, baseline hemoglobin level, and baseline erythropoietin level were not predictive of a positive response to treatment. Epoetin alfa was well tolerated. CONCLUSION: Epoetin alfa appears to have a beneficial impact on patient- reported functional capacity and quality of life in patients with cancer who received chemotherapy independent of tumor response. Concordantly, epoetin alfa appeared to increase hemoglobin levels and decrease transfusion use. Patients responded across all tumor types. The results suggest that epoetin alfa effectively improves functional outcomes in patients with cancer who receive chemotherapy.


This article has been cited by other articles:


Home page
 The OncologistHome page
M. S. Aapro and H. Link
September 2007 Update on EORTC Guidelines and Anemia Management with Erythropoiesis-Stimulating Agents
Oncologist, May 1, 2008; 13(suppl_3): 33 - 36.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
P. Pedrazzoli, A. Farris, S. Del Prete, F. Del Gaizo, D. Ferrari, C. Bianchessi, G. Colucci, A. Desogus, T. Gamucci, A. Pappalardo, et al.
Randomized Trial of Intravenous Iron Supplementation in Patients With Chemotherapy-Related Anemia Without Iron Deficiency Treated With Darbepoetin Alfa
J. Clin. Oncol., April 1, 2008; 26(10): 1619 - 1625.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
Y. Suzuki, Y. Tokuda, Y. Fujiwara, H. Minami, Y. Ohashi, and N. Saijo
Weekly Epoetin Beta Maintains Haemoglobin Levels and Improves Quality of Life in Patients with Non-Myeloid Malignancies Receiving Chemotherapy
Jpn. J. Clin. Oncol., March 1, 2008; 38(3): 214 - 221.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
V. Charu, B. Saidman, A. Ben-Jacob, G. R. Justice, A. S. Maniam, D. Tomita, G. Rossi, T. Rearden, and J. Glaspy
A Randomized, Open-Label, Multicenter Trial of Immediate Versus Delayed Intervention with Darbepoetin Alfa for Chemotherapy-Induced Anemia
Oncologist, October 1, 2007; 12(10): 1253 - 1263.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
V. Charu, C. P. Belani, A. N. Gill, M. Bhatt, D. Tomita, G. Rossi, and A. Ben-Jacob
Efficacy and Safety of Every-2-Week Darbepoetin Alfa in Patients with Anemia of Cancer: A Controlled, Randomized, Open-Label Phase II Trial
Oncologist, June 1, 2007; 12(6): 727 - 737.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
R. Boccia, T. Lillie, D. Tomita, and L. Balducci
The Effectiveness of Darbepoetin Alfa Administered Every 3 Weeks on Hematologic Outcomes and Quality of Life in Older Patients With Chemotherapy-Induced Anemia
Oncologist, May 1, 2007; 12(5): 584 - 593.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
J. L. Ryan, J. K. Carroll, E. P. Ryan, K. M. Mustian, K. Fiscella, and G. R. Morrow
Mechanisms of Cancer-Related Fatigue
Oncologist, May 1, 2007; 12(suppl_1): 22 - 34.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
J. K. Carroll, S. Kohli, K. M. Mustian, J. A. Roscoe, and G. R. Morrow
Pharmacologic Treatment of Cancer-Related Fatigue
Oncologist, May 1, 2007; 12(suppl_1): 43 - 51.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
F Bellati, M Pernice, N Manci, I Palaia, F Tomao, C Marchetti, M. Zullo, L Muzii, R Angioli, and P. B. Panici
Hemoglobin variation and blood transfusion rates in patients affected by locally advanced cervical cancer undergoing neo-adjuvant chemotherapy followed by radical surgery: the role of erythropoietic growth factors
Ann. Onc., April 1, 2007; 18(4): 722 - 729.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. R. Wright, Y. C. Ung, J. A. Julian, K. I. Pritchard, T. J. Whelan, C. Smith, B. Szechtman, W. Roa, L. Mulroy, L. Rudinskas, et al.
Randomized, Double-Blind, Placebo-Controlled Trial of Erythropoietin in Non-Small-Cell Lung Cancer With Disease-Related Anemia
J. Clin. Oncol., March 20, 2007; 25(9): 1027 - 1032.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. Crawford
Erythropoietin: High Profile, High Scrutiny
J. Clin. Oncol., March 20, 2007; 25(9): 1021 - 1023.
[Full Text] [PDF]

Home page
 The OncologistHome page
D. H. Henry, N. V. Dahl, M. Auerbach, S. Tchekmedyian, and L. R. Laufman
Intravenous Ferric Gluconate Significantly Improves Response to Epoetin Alfa Versus Oral Iron or No Iron in Anemic Patients with Cancer Receiving Chemotherapy
Oncologist, February 1, 2007; 12(2): 231 - 242.
[Abstract] [Full Text] [PDF]

Home page
 Am J Health Syst PharmHome page
R. N. Schwartz
Anemia in patients with cancer: Incidence, causes, impact, management, and use of treatment guidelines and protocols
Am. J. Health Syst. Pharm., February 1, 2007; 64(3_Supplement_2): S5 - S13.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
S. Yennurajalingam and E. Bruera
Palliative Management of Fatigue at the Close of Life: "It Feels Like My Body Is Just Worn Out"
JAMA, January 17, 2007; 297(3): 295 - 304.
[Abstract] [Full Text] [PDF]

Home page
 ASH-SAPHome page
J. M. Shammo and F. M. Stewart
Hematopoietic growth factors
ASH Self-Assessment Program, January 1, 2007; 2007(1): 45 - 60.
[Full Text] [PDF]

Home page
 Ann OncolHome page
G Mustacchi, R Ceccherini, C Dellach, S Foladore, S Milani, M Leita, and M Sisto
An induction dose of epoetin {alpha} of 40 000 IU daily for three consecutive days increases and maintains hemoglobin levels in anemic cancer patients undergoing chemotherapy
Ann. Onc., November 1, 2006; 17(11): 1705 - 1708.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
Y. Morishima, M. Ogura, S. Yoneda, H. Sakai, K. Tobinai, Y. Nishiwaki, H. Minami, T. Hotta, K. Ezaki, Y. Ohe, et al.
Once-Weekly Epoetin-Beta Improves Hemoglobin Levels in Cancer Patients with Chemotherapy-Induced Anemia: A Randomized, Double-Blind, Dose-Finding Study
Jpn. J. Clin. Oncol., October 1, 2006; 36(10): 655 - 661.
[Abstract] [Full Text] [PDF]

Home page
 J Oncol Pharm PractHome page
P. Cremieux, F. Vekeman, and P. Lefebvre
Dose conversion and cost effectiveness of erythropoietic therapies in chemotherapy-related anemia: a Canadian application
Journal of Oncology Pharmacy Practice, September 1, 2006; 12(3): 165 - 178.
[Abstract] [PDF]

Home page
 Am J Health Syst PharmHome page
A. L. Goram
Every-three-week administration of darbepoetin alfa in women with chemotherapy-associated anemia.
Am. J. Health Syst. Pharm., August 15, 2006; 63(16): 1522 - 1527.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. Glaspy, S. Vadhan-Raj, R. Patel, L. Bosserman, E. Hu, R. E. Lloyd, R. V. Boccia, D. Tomita, and G. Rossi
Randomized Comparison of Every-2-Week Darbepoetin Alfa and Weekly Epoetin Alfa for the Treatment of Chemotherapy-Induced Anemia: The 20030125 Study Group Trial
J. Clin. Oncol., May 20, 2006; 24(15): 2290 - 2297.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
J.-L. Canon, J. Vansteenkiste, G. Bodoky, M. V. Mateos, L. Bastit, I. Ferreira, G. Rossi, and R. G. Amado
Randomized, double-blind, active-controlled trial of every-3-week darbepoetin alfa for the treatment of chemotherapy-induced anemia.
J Natl Cancer Inst, February 15, 2006; 98(4): 273 - 284.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
J. H. Savonije, C. J. van Groeningen, L. W. Wormhoudt, and G. Giaccone
Early Intervention with Epoetin Alfa During Platinum-Based Chemotherapy: An Analysis of Quality-of-Life Results of a Multicenter, Randomized, Controlled Trial Compared with Population Normative Data.
Oncologist, February 1, 2006; 11(2): 197 - 205.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
J. H. Savonije, C. J. van Groeningen, L. W. Wormhoudt, and G. Giaccone
Early intervention with epoetin alfa during platinum-based chemotherapy: an analysis of the results of a multicenter, randomized, controlled trial based on initial hemoglobin level.
Oncologist, February 1, 2006; 11(2): 206 - 216.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. E. Hardee, M. O. Arcasoy, K. L. Blackwell, J. P. Kirkpatrick, and M. W. Dewhirst
Erythropoietin Biology in Cancer
Clin. Cancer Res., January 15, 2006; 12(2): 332 - 339.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
A. Mancuso, M. Migliorino, S. De Santis, A. Saponiero, and F. De Marinis
Correlation between anemia and functional/cognitive capacity in elderly lung cancer patients treated with chemotherapy
Ann. Onc., January 1, 2006; 17(1): 146 - 150.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
R. J Cersosimo and D. R Jacobson
Epoetin Alfa Versus Darbepoetin Alfa in Chemotherapy-Related Anemia
Ann. Pharmacother., January 1, 2006; 40(1): 58 - 65.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
P. Nieboer, C. Buijs, S. Rodenhuis, C. Seynaeve, L. V.A.M. Beex, E. van der Wall, D. J. Richel, M. A. Nooij, E. E. Voest, P. Hupperets, et al.
Fatigue and Relating Factors in High-Risk Breast Cancer Patients Treated With Adjuvant Standard or High-Dose Chemotherapy: A Longitudinal Study
J. Clin. Oncol., November 20, 2005; 23(33): 8296 - 8304.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
A. Engert
Recombinant human erythropoietin in oncology: current status and further developments
Ann. Onc., October 1, 2005; 16(10): 1584 - 1595.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
P. Barrett-Lee, C. Bokemeyer, P. Gascon, J.W.R. Nortier, M. Schneider, D. Schrijvers, S. Van Belle, and for the Ecas Advisory Board and Participating Cent
Management of Cancer-Related Anemia in Patients with Breast or Gynecologic Cancer: New Insights Based on Results from the European Cancer Anemia Survey
Oncologist, October 1, 2005; 10(9): 743 - 757.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
B. Coiffier
Response to "Effect of Patient Exclusion Criteria on the Efficacy of Erythropoiesis-Stimulating Agents in Patients with Cancer-Related Anemia"
Oncologist, October 1, 2005; 10(9): 762 - 763.
[Full Text] [PDF]

Home page
 JCOHome page
B. Leyland-Jones, V. Semiglazov, M. Pawlicki, T. Pienkowski, S. Tjulandin, G. Manikhas, A. Makhson, A. Roth, D. Dodwell, J. Baselga, et al.
Maintaining Normal Hemoglobin Levels With Epoetin Alfa in Mainly Nonanemic Patients With Metastatic Breast Cancer Receiving First-Line Chemotherapy: A Survival Study
J. Clin. Oncol., September 1, 2005; 23(25): 5960 - 5972.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. P. Steensma and C. L. Loprinzi
Erythropoietin Use in Cancer Patients: A Matter of Life and Death?
J. Clin. Oncol., September 1, 2005; 23(25): 5865 - 5868.
[Full Text] [PDF]

Home page
 Ann OncolHome page
A. Shafqat, L. H. Einhorn, N. Hanna, G. W. Sledge, A. Hanna, B. E. Juliar, P. Monahan, and S. Bhatia
Screening studies for fatigue and laboratory correlates in cancer patients undergoing treatment{dagger}
Ann. Onc., September 1, 2005; 16(9): 1545 - 1550.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
R. Waltzman, C. Croot, G. R. Justice, M. R. Fesen, V. Charu, and D. Williams
Randomized Comparison of Epoetin Alfa (40,000 U Weekly) and Darbepoetin Alfa (200 {micro}g Every 2 Weeks) in Anemic Patients with Cancer Receiving Chemotherapy
Oncologist, September 1, 2005; 10(8): 642 - 650.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
R. Stasi, S. Amadori, T. J. Littlewood, E. Terzoli, A. C. Newland, and D. Provan
Management of Cancer-Related Anemia with Erythropoietic Agents: Doubts, Certainties, and Concerns
Oncologist, August 1, 2005; 10(7): 539 - 554.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
M. S. Duh, P. Lefebvre, J. Fastenau, C. T. Piech, and R. J. Waltzman
Assessing the Clinical Benefits of Erythropoietic Agents Using Area Under the Hemoglobin Change Curve
Oncologist, June 1, 2005; 10(6): 438 - 448.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
R. C. Leonard, M. Untch, and F. Von Koch
Management of anaemia in patients with breast cancer: role of epoetin
Ann. Onc., May 1, 2005; 16(5): 817 - 824.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
T. E. Witzig, P. T. Silberstein, C. L. Loprinzi, J. A. Sloan, P. J. Novotny, J. A. Mailliard, K. M. Rowland, S. R. Alberts, J. E. Krook, R. Levitt, et al.
Phase III, Randomized, Double-Blind Study of Epoetin Alfa Compared With Placebo in Anemic Patients Receiving Chemotherapy
J. Clin. Oncol., April 20, 2005; 23(12): 2606 - 2617.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. Chang, F. Couture, S. Young, K.-L. McWatters, and C. Y. Lau
Weekly Epoetin Alfa Maintains Hemoglobin, Improves Quality of Life, and Reduces Transfusion in Breast Cancer Patients Receiving Chemotherapy
J. Clin. Oncol., April 20, 2005; 23(12): 2597 - 2605.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
U. Reinhardt, A. Tulusan, R. Angermund, H. Lutz, and For The German Epoetin Alfa Study Group
Increased Hemoglobin Levels and Improved Quality-of-Life Assessments During Epoetin Alfa Treatment in Anemic Cancer Patients: Results of a Prospective, Multicenter German Trial
Oncologist, March 1, 2005; 10(3): 225 - 237.
[Abstract] [Full Text] [PDF]

Home page
 Am J Health Syst PharmHome page
J. D. Herrington, S. L. Davidson, D. K. Tomita, L. Green, R. E. Smith, and R. V. Boccia
Utilization of darbepoetin alfa and epoetin alfa for chemotherapy-induced anemia
Am. J. Health Syst. Pharm., January 1, 2005; 62(1): 54 - 62.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. O. Arcasoy, K. Amin, S.-C. Chou, Z. A. Haroon, M. Varia, and J. A. Raleigh
Erythropoietin and Erythropoietin Receptor Expression in Head and Neck Cancer: Relationship to Tumor Hypoxia
Clin. Cancer Res., January 1, 2005; 11(1): 20 - 27.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
F. Couture, A.R. Turner, B. Melosky, L. Xiu, R.K. Plante, C.Y. Lau, and I. Quirt
Prior Red Blood Cell Transfusions in Cancer Patients Increase the Risk of Subsequent Transfusions With or Without Recombinant Human Erythropoietin Management
Oncologist, January 1, 2005; 10(1): 63 - 71.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
K. Blackwell, P. Gascon, G. Sigounas, and L. Jolliffe
rHuEPO and Improved Treatment Outcomes: Potential Modes of Action
Oncologist, November 1, 2004; 9(suppl_5): 41 - 47.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
H. Ludwig
rHuEPO and Treatment Outcomes: The Preclinical Experience
Oncologist, November 1, 2004; 9(suppl_5): 48 - 54.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
C. A. Hudis, S. Van Belle, J. Chang, and K. Muenstedt
rHuEPO and Treatment Outcomes: the Clinical Experience
Oncologist, November 1, 2004; 9(suppl_5): 55 - 69.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
V. Voelter, C. Schuhmacher, R. Busch, C. Peschel, J. R. Siewert, and F. Lordick
Incidence of anemia in patients receiving neoadjuvant chemotherapy for locally advanced esophagogastric cancer
Ann. Thorac. Surg., September 1, 2004; 78(3): 1037 - 1041.
[Abstract] [Full Text] [PDF]

Home page
 GutHome page
C Gasche, M C E Lomer, I Cavill, and G Weiss
Iron, anaemia, and inflammatory bowel diseases
Gut, August 1, 2004; 53(8): 1190 - 1197.
[Abstract] [Full Text] [PDF]

Home page
 J Natl Cancer Inst MonogrHome page
D. P. Lawrence, B. Kupelnick, K. Miller, D. Devine, and J. Lau
Evidence Report on the Occurrence, Assessment, and Treatment of Fatigue in Cancer Patients
J Natl Cancer Inst Monographs, July 1, 2004; 2004(32): 40 - 50.
[Abstract] [Full Text] [PDF]

Home page
 J Natl Cancer Inst MonogrHome page
L. M. Nail
My Get Up and Go Got Up and Went: Fatigue in People With Cancer
J Natl Cancer Inst Monographs, July 1, 2004; 2004(32): 72 - 75.
[Abstract] [Full Text] [PDF]

Home page
 J Natl Cancer Inst MonogrHome page
S. D. Passik
Abstract: Impediments and Solutions to Improving the Management of Cancer-Related Fatigue
J Natl Cancer Inst Monographs, July 1, 2004; 2004(32): 136 - 136.
[Full Text] [PDF]

Home page
 The OncologistHome page
J. Patton, T. Reeves, and J. Wallace
Effectiveness of Darbepoetin Alfa Versus Epoetin Alfa in Patients with Chemotherapy-Induced Anemia Treated in Clinical Practice
Oncologist, July 1, 2004; 9(4): 451 - 458.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
E. Cortesi, A. Mancuso, A. De Pasquale Ceratti, N. Pizzardi, G. D'Auria, C. Accettura, P. Beccaglia, D. Bertelletti, and F. De Marinis
Effectiveness and Safety of an Induction Therapy with Epoetin Alfa in Anemic Cancer Patients Receiving Concomitant Chemotherapy
Oncologist, July 1, 2004; 9(4): 459 - 468.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
D. Cella, J. Kallich, A. McDermott, and X. Xu
The longitudinal relationship of hemoglobin, fatigue and quality of life in anemic cancer patients: results from five randomized clinical trials
Ann. Onc., June 1, 2004; 15(6): 979 - 986.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
A. Iop, A. M. Manfredi, and S. Bonura
Fatigue in cancer patients receiving chemotherapy: an analysis of published studies
Ann. Onc., May 1, 2004; 15(5): 712 - 720.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. Auerbach, H. Ballard, J. R. Trout, M. McIlwain, A. Ackerman, H. Bahrain, S. Balan, L. Barker, and J. Rana
Intravenous Iron Optimizes the Response to Recombinant Human Erythropoietin in Cancer Patients With Chemotherapy-Related Anemia: A Multicenter, Open-Label, Randomized Trial
J. Clin. Oncol., April 1, 2004; 22(7): 1301 - 1307.
[Abstract] [Full Text] [PDF]